Clinical Development International Pharmacokinetics Therapies 
Advarra
JUNE 20, 2023
Additionally, in 2021, a literature review estimated the average capitalized research and development (R&D) costs per new cancer medicine at between $944 million and $4.54 Typical clinical development timelines for anticancer drugs average an estimated 6.7 This means study startup times can vary greatly.
The Pharma Data
AUGUST 19, 2021
Oral presentation at the International Association for the Study of Lung Cancer’s (IASLC) 2021 World Conference on Lung Cancer (WCLC) shows evidence that the bispecific mechanism of action for RYBREVANT TM can provide anti-tumor activity against either EGFR-mutated or MET-mutated non-small cell lung cancer. 4] , [5] , [6].
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Discovery World
AUGUST 8, 2022
The company has been investigating Mim8 in its Phase I & II FRONTIER1 study and recently reported positive interim results from the study at the International Society of Thrombosis and Haemostasis Annual Congress (ISTH 2022) in London, UK. . Zero bleeds were reported in the eight participants treated with the therapy once monthly. .
The Pharma Data
AUGUST 29, 2020
Oral, investigational complement factor B inhibitor LNP023 substantially improved hematological response as add-on therapy to eculizumab. To date, after at least six months of stable LNP023 add-on therapy, and at the investigators’ discretion, seven patients (70%) have discontinued eculizumab and remained on LNP023 as monotherapy.
The Pharma Data
SEPTEMBER 1, 2020
Pregnancy outcomes in the ozanimod multiple sclerosis clinical development program. Inhibition of drug transporter breast cancer resistance protein has no effect on the pharmacokinetics of major active metabolites of ozanimod. Presentation Topic: Disease Modifying Therapies – Risk Management. Author: Minton. Author: Fox.
The Pharma Data
JULY 21, 2021
These data were shared as a late-breaking oral presentation during the virtual 11 th International AIDS Society Conference on HIV Science (IAS 2021) and are a follow-up to the interim analysis that was presented earlier this year at the virtual 2021 HIV Research for Prevention Conference (HIVR4P 2021). “The
The Pharma Data
NOVEMBER 4, 2020
Food and Drug Administration (FDA) Breakthrough Therapy and Fast Track Designations, is now in pivotal testing, and CTP-692 for schizophrenia is currently on track for topline data readout in the first quarter of 2021,” said Roger Tung, Ph.D., and Canada) or (484) 365-2865 (International) five minutes prior to the start time.
Expert insights. Personalized for you.
52 
Let's personalize your content